323 related articles for article (PubMed ID: 37893423)
1. Robust Identification of Differential Gene Expression Patterns from Multiple Transcriptomics Datasets for Early Diagnosis, Prognosis, and Therapies for Breast Cancer.
Tuly KF; Hossen MB; Islam MA; Kibria MK; Alam MS; Harun-Or-Roshid M; Begum AA; Hasan S; Mahumud RA; Mollah MNH
Medicina (Kaunas); 2023 Sep; 59(10):. PubMed ID: 37893423
[No Abstract] [Full Text] [Related]
2. Statistics and network-based approaches to identify molecular mechanisms that drive the progression of breast cancer.
Alam MS; Rahaman MM; Sultana A; Wang G; Mollah MNH
Comput Biol Med; 2022 Jun; 145():105508. PubMed ID: 35447458
[TBL] [Abstract][Full Text] [Related]
3. Robust identification of common genomic biomarkers from multiple gene expression profiles for the prognosis, diagnosis, and therapies of pancreatic cancer.
Hossen MB; Islam MA; Reza MS; Kibria MK; Horaira MA; Tuly KF; Faruqe MO; Kabir F; Mollah MNH
Comput Biol Med; 2023 Jan; 152():106411. PubMed ID: 36502691
[TBL] [Abstract][Full Text] [Related]
4. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.
Ahmed FF; Reza MS; Sarker MS; Islam MS; Mosharaf MP; Hasan S; Mollah MNH
PLoS One; 2022; 17(4):e0266124. PubMed ID: 35390032
[TBL] [Abstract][Full Text] [Related]
5. Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies.
Alam MS; Sultana A; Reza MS; Amanullah M; Kabir SR; Mollah MNH
PLoS One; 2022; 17(5):e0268967. PubMed ID: 35617355
[TBL] [Abstract][Full Text] [Related]
6. Metadata analysis to explore hub of the hub-genes highlighting their functions, pathways and regulators for cervical cancer diagnosis and therapies.
Reza MS; Hossen MA; Harun-Or-Roshid M; Siddika MA; Kabir MH; Mollah MNH
Discov Oncol; 2022 Aug; 13(1):79. PubMed ID: 35994213
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel biomarkers in breast cancer via integrated bioinformatics analysis and experimental validation.
Wang N; Zhang H; Li D; Jiang C; Zhao H; Teng Y
Bioengineered; 2021 Dec; 12(2):12431-12446. PubMed ID: 34895070
[TBL] [Abstract][Full Text] [Related]
8. Identification of Drug Targets and Agents Associated with Hepatocellular Carcinoma through Integrated Bioinformatics Analysis.
Hossen MA; Reza MS; Harun-Or-Roshid M; Islam MA; Siddika MA; Mollah MNH
Curr Cancer Drug Targets; 2023; 23(7):547-563. PubMed ID: 36786134
[TBL] [Abstract][Full Text] [Related]
9. Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections.
Sarker B; Rahaman MM; Islam MA; Alamin MH; Husain MM; Ferdousi F; Ahsan MA; Mollah MNH
PLoS One; 2023; 18(3):e0281981. PubMed ID: 36913345
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer.
Alam MS; Sultana A; Wang G; Haque Mollah MN
Front Mol Biosci; 2022; 9():1049741. PubMed ID: 36567949
[TBL] [Abstract][Full Text] [Related]
11. Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis.
Chen G; Yu M; Cao J; Zhao H; Dai Y; Cong Y; Qiao G
Bioengineered; 2021 Dec; 12(1):5149-5161. PubMed ID: 34384030
[TBL] [Abstract][Full Text] [Related]
12. Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis.
Fang E; Zhang X
Cancer Biomark; 2017 Dec; 21(1):373-381. PubMed ID: 29081411
[TBL] [Abstract][Full Text] [Related]
13. Screening and Identification of Key Biomarkers in Inflammatory Breast Cancer Through Integrated Bioinformatic Analyses.
Wu J; Lv Q; Huang H; Zhu M; Meng D
Genet Test Mol Biomarkers; 2020 Aug; 24(8):484-491. PubMed ID: 32598242
[No Abstract] [Full Text] [Related]
14. Bioinformatics screening of colorectal-cancer causing molecular signatures through gene expression profiles to discover therapeutic targets and candidate agents.
Horaira MA; Islam MA; Kibria MK; Alam MJ; Kabir SR; Mollah MNH
BMC Med Genomics; 2023 Mar; 16(1):64. PubMed ID: 36991484
[TBL] [Abstract][Full Text] [Related]
15. In silico analysis of differentially expressed-aberrantly methylated genes in breast cancer for prognostic and therapeutic targets.
Gadwal A; Purohit P; Khokhar M; Vishnoi JR; Pareek P; Choudhary R; Elhence P; Banerjee M; Sharma P
Clin Exp Med; 2023 Nov; 23(7):3847-3866. PubMed ID: 37029310
[TBL] [Abstract][Full Text] [Related]
16. Integrated bioinformatics analyses identifying potential biomarkers for type 2 diabetes mellitus and breast cancer: In SIK1-ness and health.
Durrani IA; Bhatti A; John P
PLoS One; 2023; 18(8):e0289839. PubMed ID: 37556419
[TBL] [Abstract][Full Text] [Related]
17. Identification of Methylation Markers and Differentially Expressed Genes with Prognostic Value in Breast Cancer.
Wu J; Zhang Y; Li M
J Comput Biol; 2019 Dec; 26(12):1394-1408. PubMed ID: 31290690
[TBL] [Abstract][Full Text] [Related]
18. Expression and potential molecular mechanisms of miR‑204‑5p in breast cancer, based on bioinformatics and a meta‑analysis of 2,306 cases.
Cai KT; Liu AG; Wang ZF; Jiang HW; Zeng JJ; He RQ; Ma J; Chen G; Zhong JC
Mol Med Rep; 2019 Feb; 19(2):1168-1184. PubMed ID: 30569120
[TBL] [Abstract][Full Text] [Related]
19. Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
PLoS One; 2021; 16(11):e0254283. PubMed ID: 34797837
[TBL] [Abstract][Full Text] [Related]
20. Identification and Verification of Key Tumor Genes Associated with Diagnosis and Prognosis of Breast Cancer Based on Bioinformatics Analysis.
Yu F; Pan XJ; Luo J
Dis Markers; 2022; 2022():9041466. PubMed ID: 35686034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
